... to prospectively evaluate the antiviral responses and evolution of resistance mutations during adefovir (ADV) plus lamivudine (LMV) therapy in patients with entecavir (ETV)-resistant hepatitis B virus (HBV) infection. Methods: Twenty chronic hepatitis B (CHB) patients who had been receiving ETV for more than 6...

...Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada Aims: The long-term efficacy of adefovir dipivoxil in combination with lamivudine to chronic hepatitis B...

...Do Young Kim; Sang Hoon Ahn; Hyun Woong Lee; Jun Yong Park; Seung Up Kim; Yong Han Paik; Kwan Sik Lee; Kwang-Hyub Han; Chae Yoon Chon Objective: High rate of resistance to lamivudine is a major problem in treating chronic hepatitis B (CHB) patients. We investigated the course of virologic...

...Elmar Jaeckel; Michael P. Manns After several nucleoside analogues have been tested against chronic hepatitis B virus (HBV) infection with minimal success, lamivudine seems to be a highly effective new therapeutic option. This review focusses on nucleoside metabolism and on the molecular action...

...Eiji Tanaka; Akihiro Matsumoto; Kaname Yoshizawa; Noboru Maki Objective: The clinical significance of the hepatitis B virus core-related antigen (HBcrAg) assay in monitoring the antiviral effects of lamivudine is reviewed. Methods: The HBcrAg assay simultaneously measured serum levels of hepatitis...

...: To investigate the frequency and profile of naturally occurring S-gene mutants and the influence of long-term lamivudine therapy in patients with chronic hepatitis B (CHB). Materials and Methods: 57 patients with histologically proven CHB, on lamivudine 100 mg/day for more than 24 months, were included. Viral...

...Seung Kew Yoon; Jeong Won Jang; Chang Wook Kim; Si Hyun Bae; Jong Young Choi; Sang Wook Choi; Young Sok Lee; Chang Don Lee; Kyu Won Chung; Hee Sik Sun; Boo Sung Kim Objective: The aim of this study was to evaluate retrospectively the long-term effects of lamivudine in 461 Korean patients...

...Hiroyuki Nakanishi; Masayuki Kurosaki; Yasuhiro Asahina; Yuko Onuki; Ken Ueda; Yuki Nishimura; Kaoru Tsuchiya; Takatoshi Kitamura; Masakatsu Uchihara; Shozo Miyake; Nobuyuki Enomoto; Namiki Izumi Breakthrough hepatitis remains the major issue in long-term lamivudine therapy for chronic hepatitis B...

... often occur spontaneously and follow a fulminating progression to fatal hepatic failure. The aim of this study was to clarify potential factors, including benefit of lamivudine therapy, which could influence clinical course of the serious disease in an area of intermediate HBV endemicity. Methods...

... to be only 14–35%. While the ultimate treatment of decompensated cirrhosis is orthotopic liver transplantation (OLT), recent studies have suggested that lamivudine can also improve the clinical outcomes in this group of patients. Lamivudine rapidly suppresses HBV replication and can improve several...

.... In other words, HBV is not completely eliminated. Viral breakthrough occurs with noncompliance to therapy and, also, when drug-resistant mutants emerge. Mutations in the YMDD motif of HBV polymerase lead to resistance to antivirals, such as lamivudine and famciclovir. In clinical practice, the diagnosis...

...Takeshi Okanoue; Kojiro Mori; Toshihiko Kirishima; Koji Kunimoto; Kohichiroh Yasui; Yoshito Itoh; Masahito Minami Objective: The aim of this study was to investigate the emergence of YMDD mutants in patients with chronic hepatitis B during lamivudine therapy and to compare the emergence patterns...

...Fumitaka Suzuki Objective: The optimal therapeutic regimen of lamivudine for chronic hepatitis B is not agreed upon, especially with reference to hepatitis B e antigen (HBeAg) or the corresponding antibody (anti-HBe) in sera of patients. Methods: We analyzed 249 Japanese patients with chronic HBV...

... complications. The response to lamivudine therapy was evaluated in 21 patients infected with HBV genotype B (all of subtype Ba) and 61 with genotype C. There were no differences in the virological response to lamivudine therapy, based on the reduction in median logarithmic HBV DNA titer as well as alanine...

...Hiroshi Yotsuyanagi; Kiyomi Yasuda; Shiro Iino Short-term lamivudine and its withdrawal were evaluated as regards an immunomodulatory therapy of chronic hepatitis B. Lamivudine was given for 3 or 6 months to 23 patients with chronic hepatitis B who were infected with hepatitis B virus (HBV...

.... This article reviews recently published clinical data on the two currently available antivirals for the treatment of chronic hepatitis B infection, lamivudine and adefovir dipivoxil. Lamivudine, a nucleoside analogue, is currently the only licensed antiviral for the treatment of chronic hepatitis B in Asia...

...Waka Ohishi; Kazuaki Chayama The emergence of drug-resistant mutants of hepatitis B virus (HBV) is a serious problem during antiviral therapy of patients with chronic hepatitis B. Lamivudine-resistant mutants with a mutation in the YMDD motif of reverse transcriptase of HBV emerge in approximately...

...Rong-Nan Chien; Yun-Fan Liaw Lamivudine is a nucleoside analogue with potent inhibitory effects on hepatitis B virus (HBV) polymerase/reverse transcriptase activity. The rate of hepatitis B e antigen (HBeAg) seroconversion in a large series of Asian patients treated with lamivudine 100 mg daily...

...Hiromitsu Kumada From September 1995 through April 2002, 286 patients with chronic hepatitis B were started on lamivudine at the Toranomon Hospital in Tokyo, Japan, and most of them continued with it. At present, 16 patients received lamivudine for 5 years, 7 of whom for 7 years or longer. YMDD...

...Ryukichi Kumashiro; Reiichiro Kuwahara; Tatsuya Ide; Yuriko Koga; Teruko Arinaga; Akiko Hisamochi; Kei Ogata; Kazuo Tanaka; Michio Sata Breakthroughs during lamivudine therapy were assessed according to hepatitis flares and mutational polymorphism of hepatitis B virus (HBV) infecting patients...